Stocks · News reference
UBS Maintains 75% Success Probability for Ocular Therapeutix's Axpaxli in Wet AMD
UBS analysts reaffirmed a 75% probability of success for Ocular Therapeutix's Axpaxli in treating wet age-related macular degeneration following a competitor's trial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — OCULAR THERAPEUTIX, INC (OCUL)
Filed: 2026-10-16 AccNo: 0001104659-26-116617 Size: 183 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
UBS Initiates Coverage On Ocular Therapeutix with Buy Rating, Announces Price Target of $14